Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study

Background: There is underutilization of long-acting injectable (LAI) antipsychotics for first-episode schizophrenia (FES) despite having convenient dosing and treatment retention. LAIs are predominantly used for patients with poor compliance, chronic course, and multiple relapses. Materials and Met...

Full description

Saved in:
Bibliographic Details
Main Authors: Ramandeep Kaur, Ajeet Sidana, Nidhi Malhotra, Shikha Tyagi
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-04-01
Series:Indian Journal of Psychiatry
Subjects:
Online Access:https://journals.lww.com/10.4103/indianjpsychiatry.indianjpsychiatry_389_22
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832593599203639296
author Ramandeep Kaur
Ajeet Sidana
Nidhi Malhotra
Shikha Tyagi
author_facet Ramandeep Kaur
Ajeet Sidana
Nidhi Malhotra
Shikha Tyagi
author_sort Ramandeep Kaur
collection DOAJ
description Background: There is underutilization of long-acting injectable (LAI) antipsychotics for first-episode schizophrenia (FES) despite having convenient dosing and treatment retention. LAIs are predominantly used for patients with poor compliance, chronic course, and multiple relapses. Materials and Methods: Seventy-two treatment naïve patients with the first episode of Schizophrenia (DSM-5) were assessed for baseline severity of psychopathology using the positive and negative syndrome scale (PANSS) and quality of life (QOL) using the WHOQOL-BREF scale. Patients were randomized to receive either oral haloperidol or LAI haloperidol for a period of 12 weeks. Results: Both the groups had a significant reduction in PANSS scores and improvement in QoL over 12 weeks period (P = 0.0001). The LAI group showed greater adherence and significantly better quality of life than the oral group (P = 0.023). The mean numbers of side effects were less in the LAI group at week 2 as compared to the oral group. Conclusion: LAI haloperidol is similar to oral haloperidol in patients with FES with respect to treatment response and offers benefits in form of a lesser number of side effects during early treatment, overall better adherence rates, and better QOL.
format Article
id doaj-art-23f063b49b5a44cbbc2a21d5b75117ba
institution Kabale University
issn 0019-5545
1998-3794
language English
publishDate 2023-04-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Indian Journal of Psychiatry
spelling doaj-art-23f063b49b5a44cbbc2a21d5b75117ba2025-01-20T11:14:26ZengWolters Kluwer Medknow PublicationsIndian Journal of Psychiatry0019-55451998-37942023-04-0165440441110.4103/indianjpsychiatry.indianjpsychiatry_389_22Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional studyRamandeep KaurAjeet SidanaNidhi MalhotraShikha TyagiBackground: There is underutilization of long-acting injectable (LAI) antipsychotics for first-episode schizophrenia (FES) despite having convenient dosing and treatment retention. LAIs are predominantly used for patients with poor compliance, chronic course, and multiple relapses. Materials and Methods: Seventy-two treatment naïve patients with the first episode of Schizophrenia (DSM-5) were assessed for baseline severity of psychopathology using the positive and negative syndrome scale (PANSS) and quality of life (QOL) using the WHOQOL-BREF scale. Patients were randomized to receive either oral haloperidol or LAI haloperidol for a period of 12 weeks. Results: Both the groups had a significant reduction in PANSS scores and improvement in QoL over 12 weeks period (P = 0.0001). The LAI group showed greater adherence and significantly better quality of life than the oral group (P = 0.023). The mean numbers of side effects were less in the LAI group at week 2 as compared to the oral group. Conclusion: LAI haloperidol is similar to oral haloperidol in patients with FES with respect to treatment response and offers benefits in form of a lesser number of side effects during early treatment, overall better adherence rates, and better QOL.https://journals.lww.com/10.4103/indianjpsychiatry.indianjpsychiatry_389_22adherenceantipsychoticfesfirst-episode schizophrenialaiquality of life
spellingShingle Ramandeep Kaur
Ajeet Sidana
Nidhi Malhotra
Shikha Tyagi
Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study
Indian Journal of Psychiatry
adherence
antipsychotic
fes
first-episode schizophrenia
lai
quality of life
title Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study
title_full Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study
title_fullStr Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study
title_full_unstemmed Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study
title_short Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study
title_sort oral versus long acting injectable antipsychotic in first episode schizophrenia a 12 weeks interventional study
topic adherence
antipsychotic
fes
first-episode schizophrenia
lai
quality of life
url https://journals.lww.com/10.4103/indianjpsychiatry.indianjpsychiatry_389_22
work_keys_str_mv AT ramandeepkaur oralversuslongactinginjectableantipsychoticinfirstepisodeschizophreniaa12weeksinterventionalstudy
AT ajeetsidana oralversuslongactinginjectableantipsychoticinfirstepisodeschizophreniaa12weeksinterventionalstudy
AT nidhimalhotra oralversuslongactinginjectableantipsychoticinfirstepisodeschizophreniaa12weeksinterventionalstudy
AT shikhatyagi oralversuslongactinginjectableantipsychoticinfirstepisodeschizophreniaa12weeksinterventionalstudy